Lascufloxacin Hydrochloride(Lascufloxacin Hydrochloride) - 药物靶点：Bacterial DNA gyrase x Bacterial top IV_在研适应症：肺脓肿，肺炎，下呼吸道感染_专利_临床

概要

基本信息

药物类型

小分子化药

别名

KRP-AM1977、LSFX、Lascufloxacin

+ [8]

靶点

Bacterial DNA gyrase x Bacterial top IV

作用机制

细菌DNA旋转酶复合体抑制剂、Bacterial top IV抑制剂(细菌拓扑异构酶IV抑制剂)

治疗领域

感染呼吸系统疾病其他疾病

在研适应症

肺脓肿肺炎下呼吸道感染

非在研适应症-

原研机构

KYORIN Pharmaceutical Co., Ltd.

在研机构

KYORIN Pharmaceutical Co., Ltd.

非在研机构-

最高研发阶段批准上市

首次获批日期

日本 (2020-11-27),

肺脓肿肺炎

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C21H24F3N3O4

InChIKeyZFIOCUITTUUVPV-MEDUHNTESA-N

CAS号848416-07-9

关联

36

项与 Lascufloxacin Hydrochloride 相关的临床试验

JPRN-jRCTs071230001 / Not yet recruiting临床4期IIT

Study protocol: Evaluation of efficacy and safety of Lascufloxacin in switch therapy for community-acquired pneumonia: a single arm, open-label clinical trial

开始日期2023-05-22

申办/合作机构

KYORIN Pharmaceutical Co., Ltd.

JPRN-jRCTs071200066 / Not yet recruiting临床4期IIT

Study protocol: Evaluation of efficacy and safety of Lascufloxacin for Nursing and Healthcare Associated Pneumonia: single arm, open-label clinical trial

开始日期2021-03-30

申办/合作机构

KYORIN Pharmaceutical Co., Ltd.

JPRN-jRCTs031200219 / CompletedN/AIIT

Lascufloxacin penetration into otorhinolaryngological tissues study - LSPOT Study

开始日期2021-03-02

申办/合作机构-

100 项与 Lascufloxacin Hydrochloride 相关的临床结果

登录后查看更多信息

100 项与 Lascufloxacin Hydrochloride 相关的转化医学

登录后查看更多信息

100 项与 Lascufloxacin Hydrochloride 相关的专利（医药）

登录后查看更多信息

25

项与 Lascufloxacin Hydrochloride 相关的文献（医药）

2024-09-01·International Journal of Infectious Diseases

Lobar pneumonia due to human metapneumovirus: a case report

Article

作者: Kawataki, Masanori ; Koyama, Takashi ; Ito, Akihiro ; Ishida, Tadashi

Human metapneumovirus (hMPV) is a respiratory pathogen that can cause lower respiratory tract infections and pneumonia in immunocompetent adults. Pneumonia caused by hMPV is reportedly more likely to cause bronchial wall thickening and ground-glass opacity (GGO). A 44-year-old woman with no significant medical history developed fever, cough, and nausea. Computed tomography of the chest showed scattered GGOs in the right upper lobe and infiltrating shadows with air bronchograms in the left lingual and bilateral lower lobes. The patient was admitted to our hospital for further evaluation. Atypical pneumonia was suspected and lascufloxacin (LSFX) was started. Multiplex polymerase chain reaction (PCR) detected hMPV on hospital day 2 using the FilmArray Respiratory Panel 2.1. Pneumonia due to hMPV was suspected and LSFX was discontinued. The patient subsequently showed spontaneous improvement and was discharged on hospital day 6 after admission. After discharge, pneumonia continued to improve. Early detection of respiratory pathogens using multiplex PCR can help determine the appropriate treatment strategy. As hMPV can also cause lobar pneumonia, we should consider pneumonia due to hMPV in the differential diagnosis of lobar pneumonia.

2024-07-01·Journal of Infection and Chemotherapy

Efficacy and safety of lascufloxacin for nursing- and healthcare-associated pneumonia: A single-arm, open-label clinical trial

Article

作者: Fukushima, Kiyoyasu ; Kondo, Akira ; Fukuda, Yuichi ; Inoue, Yuichi ; Ide, Shotaro ; Iwanaga, Naoki ; Imamura, Yoshifumi ; Irifune, Satoshi ; Hanaka, Tetsuya ; Suyama, Naofumi ; Ito, Yuya ; Yanagihara, Katsunori ; Tanaka, Hikaru ; Mihara, Tomo ; Sasaki, Eisuke ; Harada, Yosuke ; Takeda, Kazuaki ; Morikawa, Toru ; Sawai, Toyomitsu ; Nakada, Nana ; Yatera, Kazuhiro ; Shimabukuro, Ikuko ; Funada, Midori ; Yoshida, Masataka ; Hata, Ryosuke ; Futsuki, Yoji ; Morio, Ryosuke ; Fukushima, Koki ; Izumikawa, Koichi ; Morimoto, Shimpei ; Hosogaya, Naoki ; Ota, Kenji ; Nemoto, Kazuki ; Nagayoshi, Yosuke ; Mukae, Hiroshi ; Miyamura, Takuto ; Takazono, Takahiro

BACKGROUNDNursing- and healthcare-associated pneumonia (NHCAP) constitutes most of the pneumonia in elderly patients including aspiration pneumonia in Japan. Lascufloxacin (LSFX) possesses broad antibacterial activity against respiratory pathogens, such as Streptococcus spp. And anaerobes inside the oral cavity. However, the efficacy and safety of LSFX in NHCAP treatment remains unknown. We aimed to evaluate the efficacy and safety of LSFX tablets in the treatment of patients with NHCAP.METHODSIn this single-arm, open-label, uncontrolled study, LSFX was administered to patients with NHCAP at 24 facilities. The study participants were orally administered 75 mg LSFX once daily for 7 days. The primary endpoint was the clinical efficacy at the time of test of cure (TOC). The secondary endpoints included clinical efficacy at the time of end of treatment (EOT), early clinical efficacy, microbiological efficacy, and safety analysis.RESULTDuring the study period, 75 patients provided written informed consent to participate and were included. Finally, 56 and 71 patients were eligible for clinical efficacy and safety analyses, respectively. The median age of the patients was significantly high at 86 years. All patients were classified as having moderate disease severity using the A-DROP scoring system. LSFX tablets demonstrated high efficacy rates of 78.6 % at TOC and 89.3 % at EOT. The risk factors for resistant bacteria or aspiration pneumonia did not affect clinical efficacy. No severe adverse events associated with the study drugs were observed.CONCLUSIONOral LSFX is an acceptable treatment option for moderate NHCAP in elderly patients who can take oral medications.

2024-07-01·Journal of Infection and Chemotherapy

Temporal effects of lascufloxacin on human gut and salivary microbiota: Analysis using next-generation sequencing method

Article

作者: Endo, Yusuke ; Morishima, So ; Oda, Machi ; Mukuda, Kengo ; Doi, Ayumu ; Inoue, Ryo ; Nishikawa, Yukari ; Ma'arif, Athok Shofiudin ; Chikumi, Hiroki ; Noma, Hisashi ; Sunada, Hiroshi ; Matsuda, Risa ; Okada, Kensaku ; Nakamoto, Masaki ; Kitaura, Tsuyoshi ; Takata, Miyako ; Yamasaki, Akira ; Takazawa, Kenji

INTRODUCTIONAntimicrobial treatment disrupts human microbiota. The effects of lascufloxacin (LSFX), a new fluoroquinolone, on human microbiota remains unknown. Therefore, in this study, we aimed to evaluate the effects of LSFX administration on the gut and salivary microbiota of healthy participants and those with pneumonia.METHODSLSFX (75 mg, once a day, orally) was administered to healthy adults (healthy group) and adult patients with pneumonia (pneumonia group), and fecal and saliva samples were collected at five time points (Days 0, 3, 7, 14, and 28). Using the collected samples, α- and β-diversity indices, as well as bacterial composition of the gut microbiota and salivary microbiota were analyzed using next-generation sequencing.RESULTSIn the healthy group, α-diversity indices of the gut and salivary microbiota were reduced and the lowest values on Day 3. For the gut microbiota, the Chao1 index (richness) recovered on Day 28, whereas the Shannon index (evenness) did not. In the salivary microbiota, the Chao1 and Shannon indices did not recover within the 28 day period. The β-diversity indices changed after LSFX administration and subsequently recovered on Day 28. After LSFX administration, the abundance of the Lachnospiraceae family decreased in the gut microbiota, and the abundance of Granulicatella, Streptococcus, Prevotella, Absconditabacteriales(SR1), and Saccharimonadales decreased in the salivary microbiota. In the pneumonia group, the α-diversity indices were lowest on Day 14 after LSFX administration.CONCLUSIONSWe elucidated that LSFX administration differentially affected the gut and salivary microbiota; however, the richness and beta diversity recovered within 28 days.

1

项与 Lascufloxacin Hydrochloride 相关的新闻（医药）

2019-09-27

·BioPortfolio

Pipeline Watch: Roxadustat, Lascufloxacin Approvals In Japan

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical... Related Stories Genmab Cash Pile To Grow With Another Darzalex OK Jazz Poised To Hold Onto Strong Sleep Disorder Position Novartis Bemused As NICE Says No Again To Migraine Drug Aimovig

100 项与 Lascufloxacin Hydrochloride 相关的药物交易

登录后查看更多信息